新抗体被批准用于治疗类风湿性关节炎

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996) Pub Date : 2003-03-01 DOI:10.1331/108658003321480812

Peggy Piascik PhD (Associate professor of pharmacy practice and science)

{"title":"新抗体被批准用于治疗类风湿性关节炎","authors":"Peggy Piascik PhD (Associate professor of pharmacy practice and science)","doi":"10.1331/108658003321480812","DOIUrl":null,"url":null,"abstract":"Adalimumab joins free existing biologic agents for the treatment of RA. Its place among these therapeutic options is unclear until head-to-head studies are performed with adalimumab and other biologic DMARDs. Adalimumab is currently in clinical trials for additional therapeutic uses, namely Crohn's disease and coronary artery disease.","PeriodicalId":79444,"journal":{"name":"Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)","volume":"43 2","pages":"Pages 327-328"},"PeriodicalIF":0.0000,"publicationDate":"2003-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1331/108658003321480812","citationCount":"5","resultStr":"{\"title\":\"New Antibody Approved for Treatment of Rheumatoid Arthritis\",\"authors\":\"Peggy Piascik PhD (Associate professor of pharmacy practice and science)\",\"doi\":\"10.1331/108658003321480812\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Adalimumab joins free existing biologic agents for the treatment of RA. Its place among these therapeutic options is unclear until head-to-head studies are performed with adalimumab and other biologic DMARDs. Adalimumab is currently in clinical trials for additional therapeutic uses, namely Crohn's disease and coronary artery disease.\",\"PeriodicalId\":79444,\"journal\":{\"name\":\"Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)\",\"volume\":\"43 2\",\"pages\":\"Pages 327-328\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2003-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1331/108658003321480812\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1086580215300176\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1086580215300176","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

摘要

阿达木单抗加入了治疗类风湿性关节炎的免费现有生物制剂。在阿达木单抗和其他生物dmard进行正面研究之前，它在这些治疗方案中的地位尚不清楚。阿达木单抗目前正在临床试验中用于其他治疗用途，即克罗恩病和冠状动脉疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

New Antibody Approved for Treatment of Rheumatoid Arthritis

Adalimumab joins free existing biologic agents for the treatment of RA. Its place among these therapeutic options is unclear until head-to-head studies are performed with adalimumab and other biologic DMARDs. Adalimumab is currently in clinical trials for additional therapeutic uses, namely Crohn's disease and coronary artery disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)

自引率

0.00%

发文量